Chronic Lymphocytic Leukemia
New chronic lymphocytic leukemia data have been reported by P. Hillmen and co-authors
Published in Blood Weekly, May 1st, 2008
" We conducted a randomized trial to evaluate the efficacy and safety of intravenous alemtuzumab compared with chlorambucil in first-line treatment of chronic lymphocytic leukemia (CLL). Patients and Methods Patients received alemtuzumab (30 mg three times per week, for up to 12 weeks) or chlorambucil (40 mg/m(2) every 28 days, for up to 12 months)," scientists writing in the Journal of Clinical Oncology report.
"The primary end point was progression-free survival (PFS). Secondary end points included overall response rate (ORR), complete response (CR), time to alternative therapy, safety, and overall survival. We randomly assigned 297 patients, 149 to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2008-05-01)
More Articles from Blood Weekly
- Cystic Fibrosis
Lung transplants not dangerous for children with cystic fibrosis, after all - Abscess
Researchers from University of Iowa describe findings in abscess - Anesthesia
Research from Sangart, Inc. in the area of anesthesia published - Atherosclerosis
New atherosclerosis study findings have been reported from M.F. Engberink et al - Bioengineering
Data on bioengineering reported by researchers at University of Wisconsin, Medical Department - Blood Safety
Recent studies from American University of Beirut, Medical Department add new data to blood safety - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
